Aequus BioPharma: Developing Equitable Biomedicines™
Aequus BioPharma was formed in May, 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. (CTI) to discover, develop and market biotherapeutics based upon the proprietary Genetic Polymer™ technology platform invented at CTI. Our technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals.
Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer™ carrier domain. We believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.
About Equitable Biomedicines™
Our mission is to develop Equitable Biomedicines™: Exceptional biopharmaceuticals that provide superior value to patients
Biopharmaceuticals are inherently difficult to discover and develop, and are also expensive to manufacture and sell. These difficulties have often caused a significant delay from the time of laboratory discovery until a biotherapeutic is marketed and made available to patients. In addition, these difficulties, and the resulting investments made by biopharmaceutical manufacturers have, in part, led to the price premium often associated with biopharmaceutical products.
Aequus aims to develop Equitable Biomedicines. We believe that our technology will contribute to a reduction in the technical difficulties and overall time and expense associated with biopharmaceutical development and manufacture, reducing the time it takes for patients to benefit from breakthrough scientific discoveries. If we are successful in our mission, we will price our products in a fair and equitable manner, one that simultaneously provides value, safety and efficacy to patients and yet provides a fair return to our employees, investors and other stakeholders.
